SANTARUS INC 4
Accession 0001209191-14-001782
Filed
Jan 5, 7:00 PM ET
Accepted
Jan 6, 4:13 PM ET
Size
59.4 KB
Accession
0001209191-14-001782
Insider Transaction Report
- Disposition to Issuer
Stock Options (right to buy)
2014-01-02$28.67/sh−63,281$1,814,266→ 0 totalExercise: $3.33Exp: 2021-03-10→ Common Stock (63,281 underlying) - Award
Common Stock
2014-01-02$7.15/sh+58,208$416,187→ 58,651 total - Award
Common Stock
2014-01-02$3.33/sh+4,219$14,049→ 136,466 total - Exercise/Conversion
Stock Options (right to buy)
2014-01-02−10,276→ 68,212 totalExercise: $3.33Exp: 2021-03-10→ Common Stock (10,276 underlying) - Disposition to Issuer
Stock Options (right to buy)
2014-01-02$25.10/sh−63,584$1,595,958→ 0 totalExercise: $6.90Exp: 2017-03-12→ Common Stock (63,584 underlying) - Exercise/Conversion
Stock Options (right to buy)
2014-01-02−15,000→ 60,000 totalExercise: $6.79Exp: 2016-02-09→ Common Stock (15,000 underlying) - Award
Common Stock
2014-01-02$6.90/sh+16,416$113,270→ 90,067 total - Award
Common Stock
2014-01-02$2.36/sh+3,768$8,892→ 93,835 total - Award
Common Stock
2014-01-02$3.33/sh+10,276$34,219→ 146,742 total - Disposition to Issuer
Stock Options (right to buy)
2014-01-02$28.67/sh−68,212$1,955,638→ 0 totalExercise: $3.33Exp: 2021-03-10→ Common Stock (68,212 underlying) - Disposition to Issuer
Common Stock
2014-01-02$32.00/sh−149,710$4,790,720→ 443 total - Exercise/Conversion
Stock Options (right to buy)
2014-01-02−38,412→ 82,244 totalExercise: $4.63Exp: 2020-03-10→ Common Stock (38,412 underlying) - Disposition to Issuer
Stock Options (right to buy)
2014-01-02$27.37/sh−82,244$2,251,018→ 0 totalExercise: $4.63Exp: 2020-03-10→ Common Stock (82,244 underlying) - Exercise/Conversion
Stock Options (right to buy)
2014-01-02−16,416→ 63,584 totalExercise: $6.90Exp: 2017-03-12→ Common Stock (16,416 underlying) - Disposition to Issuer
Stock Options (right to buy)
2014-01-02$16.58/sh−93,750$1,554,375→ 0 totalExercise: $15.42Exp: 2023-03-11→ Common Stock (93,750 underlying) - Award
Common Stock
2014-01-02$6.79/sh+15,000$101,850→ 73,651 total - Award
Common Stock
2014-01-02$4.63/sh+38,412$177,848→ 132,247 total - Exercise/Conversion
Stock Options (right to buy)
2014-01-02−4,219→ 63,281 totalExercise: $3.33Exp: 2021-03-10→ Common Stock (4,219 underlying) - Exercise/Conversion
Stock Options (right to buy)
2014-01-02−58,208→ 6,792 totalExercise: $7.15Exp: 2015-02-15→ Common Stock (58,208 underlying) - Disposition to Issuer
Stock Options (right to buy)
2014-01-02$24.85/sh−6,792$168,781→ 0 totalExercise: $7.15Exp: 2015-02-15→ Common Stock (6,792 underlying) - Award
Common Stock
2014-01-02$4.93/sh+3,411$16,816→ 150,153 total - Disposition from Tender
Common Stock
2014-01-02$32.00/sh−443$14,176→ 0 total - Exercise/Conversion
Stock Options (right to buy)
2014-01-02−3,411→ 64,089 totalExercise: $4.93Exp: 2022-03-12→ Common Stock (3,411 underlying) - Disposition to Issuer
Stock Options (right to buy)
2014-01-02$27.07/sh−64,089$1,734,889→ 0 totalExercise: $4.93Exp: 2022-03-12→ Common Stock (64,089 underlying) - Exercise/Conversion
Stock Options (right to buy)
2014-01-02−3,768→ 11,393 totalExercise: $2.36Exp: 2018-03-13→ Common Stock (3,768 underlying) - Disposition to Issuer
Stock Options (right to buy)
2014-01-02$29.64/sh−11,393$337,689→ 0 totalExercise: $2.36Exp: 2018-03-13→ Common Stock (11,393 underlying) - Disposition to Issuer
Stock Options (right to buy)
2014-01-02$25.21/sh−60,000$1,512,600→ 0 totalExercise: $6.79Exp: 2016-02-09→ Common Stock (60,000 underlying) - Disposition to Issuer
Stock Options (right to buy)
2014-01-02$25.62/sh−25,000$640,500→ 0 totalExercise: $6.38Exp: 2015-09-21→ Common Stock (25,000 underlying)
Footnotes (3)
- [F1]Reflects shares of Santarus, Inc. ("Santarus") common stock, par value $0.0001 per share (the "Shares"), acquired in connection with the exercise of stock options effective and contingent upon the closing of the cash tender offer by Willow Acquisition Sub Corporation ("Merger Sub"), an indirect wholly owned subsidiary of Salix Pharmaceuticals, Ltd. ("Salix"), to purchase all of the issued and outstanding Shares at a purchase price of $32.00 per Share (the "Offer Price"), net to the seller in cash, without interest thereon and subject to any required withholding taxes, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated December 3, 2013, and in the related letter of transmittal (collectively, as each may be amended or supplemented from time to time, the "Offer").
- [F2]Reflects stock options to purchase Shares. In connection with the merger (the "Merger") of Merger Sub with and into Santarus pursuant to the Agreement and Plan of Merger, dated as of November 7, 2013 (the "Merger Agreement"), among Salix, Salix Pharmaceuticals, Inc., Merger Sub and Santarus, such stock options (i) became fully vested and exercisable prior to the effective time of the Merger and (ii) to the extent not exercised on or prior to the effective time, were cancelled and converted into the right to receive a cash payment in the amount by which the Offer Price exceeded the exercise price of the stock option as of the effective time of the Merger.
- [F3]Reflects stock options exercised effective and contingent upon the closing of the Offer.
Documents
Issuer
SANTARUS INC
CIK 0001172480
Related Parties
1- filerCIK 0001172480
Filing Metadata
- Form type
- 4
- Filed
- Jan 5, 7:00 PM ET
- Accepted
- Jan 6, 4:13 PM ET
- Size
- 59.4 KB